Private Ltd Gic Sells 1,500,000 Shares of Medline (NASDAQ:MDLN) Stock

Posted by George Bondi on Aug 19th, 2026

Medline (NASDAQ:MDLN – Get Free Report) major shareholder Private Ltd Gic sold 1,500,000 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $35.80, for a total value of $53,700,000.00. Following the completion of the transaction, the insider directly owned 22,902,482 shares of the company’s stock, valued at $819,908,855.60. This trade represents a 6.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Private Ltd Gic also recently made the following trade(s):

On Friday, August 14th, Private Ltd Gic sold 100,000 shares of Medline stock. The shares were sold at an average price of $35.80, for a total transaction of $3,580,000.00.
On Friday, August 7th, Private Ltd Gic sold 590,284 shares of Medline stock. The shares were sold at an average price of $35.58, for a total transaction of $21,002,304.72.
On Thursday, August 6th, Private Ltd Gic sold 271,994 shares of Medline stock. The stock was sold at an average price of $35.33, for a total value of $9,609,548.02.
On Wednesday, August 5th, Private Ltd Gic sold 1,976,618 shares of Medline stock. The shares were sold at an average price of $35.60, for a total value of $70,367,600.80.

Medline Trading Down 2.2%

Shares of Medline stock opened at $34.12 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.61 and a current ratio of 4.33. The company has a market capitalization of $44.86 billion and a P/E ratio of 43.19. The company’s fifty day moving average is $38.28 and its two-hundred day moving average is $41.21. Medline has a 1 year low of $32.81 and a 1 year high of $50.88.

Medline (NASDAQ:MDLN – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.18. The company had revenue of $7.68 billion during the quarter. Analysts forecast that Medline will post 1.51 earnings per share for the current year.

Hedge Funds Weigh In On Medline

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Carlyle Group Inc. bought a new stake in shares of Medline in the 4th quarter valued at approximately $9,042,728,000. H&F Corporate Investors X Ltd. acquired a new position in Medline in the fourth quarter worth $4,179,591,000. Vanguard Group Inc. bought a new stake in shares of Medline during the fourth quarter worth $793,278,000. Morgan Stanley bought a new position in shares of Medline in the fourth quarter valued at about $636,807,000. Finally, Capital Research Global Investors acquired a new position in Medline during the 4th quarter worth about $620,937,000.

Medline News Summary

Here are the key news stories impacting Medline this week:

Positive Sentiment: Medline’s latest reported quarter showed adjusted earnings of $0.50 per share, well above the $0.32 consensus estimate, on approximately $7.7 billion in revenue. Analysts continue to maintain a generally favorable view, with the stock carrying a “Moderate Buy” consensus rating. Medline stock analysis
Neutral Sentiment: Several research firms have recently reduced their price targets, including Wells Fargo to $34, JPMorgan to $46 and RBC to $46. However, JPMorgan and RBC retained bullish ratings, while the average analyst target remains substantially above the recent trading level at about $47.42. Medline analyst ratings
Negative Sentiment: Major shareholder Private Ltd GIC reported several sales totaling millions of shares. The most recent disclosures covered 1.5 million shares sold for approximately $53.7 million on August 13 and another 100,000 shares sold for $3.58 million on August 14. Repeated large-holder selling can weigh on investor sentiment and increase perceived supply of the stock. GIC Medline share sale
Negative Sentiment: Kessler Topaz Meltzer & Check and Kaplan Fox & Kilsheimer announced investigations into potential violations of federal securities laws involving Medline. The announcements are investor solicitations and do not establish wrongdoing, but they add legal uncertainty and may further pressure the stock. Medline securities investigation reminder

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft set a $37.00 price objective on shares of Medline in a research report on Thursday, August 6th. Evercore set a $39.00 price objective on Medline in a research note on Thursday, August 6th. Tigress Financial dropped their price target on Medline from $62.00 to $55.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. William Blair reiterated an “outperform” rating on shares of Medline in a report on Thursday, June 4th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Medline in a research note on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Medline has an average rating of “Moderate Buy” and an average price target of $47.42.

Check Out Our Latest Analysis on Medline

About Medline

(Get Free Report)

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.